Hao Cheng

Hao Cheng

Auto-generated profile, based on publicly available information

Hao Cheng

Department of Cardiovascular Surgery, Changhai Hospital, the Navy Medical University, Shanghai 200433, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2021 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
YZYifeng Zhou
Yifeng Zhou
YPYameng Peng
Yameng Peng
HYHao Yuan
Hao Yuan
ZLZhenyi Long
Zhenyi Long
SWSixian Wu
Sixian Wu
JYJiping Yang
Jiping Yang
Hepatitis B virus (HBV) remains one of the most serious and prevalent health problems in the world. To determine the serum hepatitis B virus (HBV) RNA levels in patients with chronic hepatitis B (CHB) with low HBV DNA levels and analyze the influencing factors. Seventy-two CHB patients with low HBV DNA levels were enrolled and divided into 2 groups according to hepatitis B e antigen (HBeAg) status; their age, sex, the incidence of HBV RNA level < lower limit of detection (LLD), and serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), quantitative determination of HBsAg (qHBsAg), HBV DNA, and HBV RNA levels were compared. The factors influencing serum HBV RNA levels < LLD and the correlation between serum HBV RNA levels, and serum ALT, AST, qHBsAg and HBV DNA levels were analyzed. In HBeAg-positive patients, serum AST, qHBsAg and HBV RNA levels were higher, and serum HBV DNA levels and incidence of HBV RNA < LLD were lower than those in HBeAg-negative patients (p < 0.05). Multivariate linear regression analysis revealed that HBeAg is a factor that significantly influences serum HBV RNA levels in patients with CHB (p < 0.05). Multivariate logistic regression analysis indicated that HBeAg and qHBsAg are factors that influence serum HBV RNA levels < LLD in patients with CHB. In HBeAg-positive patients, serum HBV RNA levels were positively correlated with qHBsAg and HBeAg. The serum HBV RNA levels in CHB patients with low HBV DNA levels varied according to HBeAg status. The HBeAg is a factor that significantly influences serum HBV RNA levels in patients with CHB, while HBeAg and qHBsAg are factors that significantly influence serum HBV RNA levels < LLD in patients with CHB.

5 August 2018 in Chinese Medical Journal
Verified
Journal Article
Open access
PDF file
HCHao Cheng
Hao Cheng
LWLiang-Yu Wu
Liang-Yu Wu
Background: Nucleoside reverse transcriptase inhibitors (NRTIs) are the earliest and most commonly used anti-human immunodeficiency virus drugs and play an important role in high active antiretroviral therapy. However, NRTI drug therapy can cause peripheral neuropathic pain. In this study, we aimed to investigate the mechanisms of rapamycin on the pain sensitization of model mice by in vivo experiments to explore the effect of mammalian target of rapamycin (mTOR) in the pathogenesis of neuropathic pain caused by NRTIs. Methods: Male Kun Ming (KM) mice weighing 20–22 g were divided into control, 2 mg/kg rapamycin, 12 mg/kg stavudine, and CMC-Na groups. Drugs were orally administered to mice for 42 consecutive days. The von Frey filament detection and thermal pain tests were conducted on day 7, 14, 21, 28, 35, and 42 after drug administration. After the last behavioral tests, immunohistochemistry and western blotting assay were used for the measurement of mTOR and other biomarkers. Multivariate analysis of variance was used. Results: The beneficial effects of rapamycin on neuropathic pain were attributed to a reduction in mammalian target of rapamycin sensitive complex 1 (mTORC1)-positive cells (70.80 ± 2.41 vs. 112.30 ± 5.66, F = 34.36, P < 0.01) and mTORC1 activity in the mouse spinal cord. Mechanistic studies revealed that Protein Kinase B (Akt)/mTOR signaling pathway blockade with rapamycin prevented the phosphorylation of mTORC1 in stavudine-intoxicated mice (0.72 ± 0.04 vs. 0.86 ± 0.03, F = 4.24, P = 0.045), as well as decreased the expression of phospho-p70S6K (0.47 ± 0.01 vs. 0.68 ± 0.03, F = 6.01, P = 0.022) and phospho-4EBP1 (0.90 ± 0.04 vs. 0.94 ± 0.06, F = 0.28, P = 0.646). Conclusions: Taken together, these results suggest that stavudine elevates the expression and activity of mTORC1 in the spinal cord through activating the Akt/mTOR signaling pathway. The data also provide evidence that rapamycin might be useful for the treatment of peripheral neuropathic pain. PI3K-Akt-mTOR 信号通路有助于缓解核苷逆转录酶抑制剂治疗 HIV 感染所并发的神经性疼痛 摘要 背景:核酸逆转录酶抑制剂(Nucleoside reverse transcriptase inhibitors, NRTIs)是临床应用最早且数量最多的抗人类免疫缺陷病毒(human immunodeficiency virus, HIV)药物,在高效抗病毒逆转录治疗(Highly active anti-retrov iral therapy, HAART)中至今仍发挥着重要的作用。但是,NRTIs类药物治疗可引起周围神经病理性疼痛。本研究将通过动物实验观察雷帕霉素干预后对造模小鼠痛敏的影响来探索哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin, mTOR)mTOR在NRTIs类药物所致神经病理性痛发生中所起的作用。 方法:体重20-22g的雄性昆明(Kun Ming, KM)小鼠分为正常组,雷帕霉素(2mg/kg)组,司他夫定组(12mg/kg)和CMC-Na组,各组连续灌胃给药42天。在给药后7、14、21、28、35、42天利用热痛敏仪和von Frey纤维检测热痛敏和机械性痛敏。行为学实验结束24h后,利用免疫组织化学和免疫印迹实验检测mTOR和其他生物标志物。使用多元方差分析进行数据统计。 结果:雷帕霉素对神经性疼痛的有益作用归因于减少小鼠脊髓中哺乳动物雷帕霉素靶蛋白敏感复合物(mammalian target of rapamycin-sensitive complex, mTORC1)阳性细胞的数目(70.80 ± 2.41 vs. 112.30 ± 5.66, F = 34.36, P < 0.01)和降低mTORC1的活性。机制研究表明雷帕霉素通过抑制mTORC1的磷酸化(0.72 ± 0.04 vs. 0.86 ± 0.03, F = 4.24, P = 0.045),同时减少磷酸化p70S6K(0.47 ± 0.01 vs. 0.68 ± 0.03, F = 6.01, P = 0.022)和磷酸化4EBP1(0.90 ± 0.04 vs. 0.94 ± 0.06, F = 0.28, P = 0.646)的表达进而抑制 Akt/mTOR信号通路的激活。 结论:研究结果表明,司他夫定通过激活Akt/mTOR信号通路提高了脊髓中mTORC1的表达和活性,该数据还提供了雷帕霉素可能用于治疗神经性疼痛的证据。

30 September 2022 in Computational Intelligence and Neuroscience
Verified
Journal Article
Open access
PDF file
YPYuanzhi Peng
Yuanzhi Peng
QZQingqing Zhang
Qingqing Zhang
HCHao Cheng
Hao Cheng
SSSaie Shen
Saie Shen
XWXiaojian Weng
Xiaojian Weng
Objective. To explore the biological function and mechanism of TREK1 in neuropathic pain. Thirty-two healthy rats and rats with sciatic nerve chronic press-fitting model (chronic constriction injury of the sciatic nerve, CCI) were selected. Western blot, immunofluorescence staining, and patch clamp technique were performed to explore the biological functions of TREK1. The expression of TREK1 was decreased in the CCI model. The TREK1 channel current in the CCI model was decreased. After local administration of TREK1 channel activator in the anterior cingulate cortex area, the pain behavior of CCI rats and the expression of TREK1 protein were reversed. The expression of TREK1 was downregulated in the ACC area of CCI rats and the current of TREK1 was decreased, which played an important role in the regulation of neuropathic pain.